Gene Therapy: Global Market Size, Share & Trends Analysis Report, 2019 -

DUBLIN--()--The "Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Cancer, Genetic Disorders, Infectious Diseases, CVD, Neuro Disorders), By Vector Type (Viral, Non-Viral), By Region, and Segment Forecasts, 2018 - 2026" report has been added to's offering.

The global gene therapy market size is expected to reach USD 5.55 billion by 2026. Rising competition among manufacturers and high number of molecules in pipeline are supporting the growth of the market.

Gene therapy development is aimed to cure rare diseases and even some hereditary diseases, which are caused by a mutated or faulty gene. Moreover, ever-increasing need for new cures for orphan diseases and rising incidence of cancer caused due to mutations in genes are likely to stir up the demand for gene therapy.

As of early 2016, there were more than 1000 molecules in the pipeline in various clinical phases. However, around 76.0% of the molecules are in the developmental or preclinical stages and expected to hit the market in late 2020's.

A great number of large pharma/biotech players are estimated to acquire small firms as many have been trying to develop in-house expertise and build their own pipelines. This trend is anticipated to help the market gain tremendous traction over the coming years. Combination of gene therapy with small molecules or protein therapy is said to have lesser side effects and better efficacy as compared to gene therapy alone.

Cancer held the dominant share in the market in 2017 owing to relatively high adoption of gene therapies for cancer treatment. Continual rise in new cancer cases and related mortality per year triggers the need for development of robust treatment options. Ongoing developments in cancer gene studies have provided significant information about cancer-related molecular signatures, which in turn, is projected to support ongoing clinical trials for cancer therapeutics.

Further Key Findings from the Study Suggest:

  • More than 60% of the market is occupied by cancer research owing to a large pipeline.
  • Adenoviral vectors are the most used in pipeline development, closely followed by retroviral vectors.
  • Europe and the U.S. are poised to occupy the largest cumulative share in the market throughout the forecast period.
  • Asia-Pacific is set to post noteworthy CAGR during the forecast period, owing to growing pipeline molecules and a large number of companies competing in the market.
  • Some of the key players in this market are UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Juno Therapeutics, GlaxoSmithKline, Celgene Corporation, Shire Plc, Sangamo Biosciences, Dimension Therapeutics, Voyager Therapeutics, Human Stem Cell Institute, Bristol Myer's Squibb, and Chiesi Farmaceutici S.p.A.

Key Topics Covered

Chapter 1 Executive Summary

Chapter 2 Market Snapshot

Chapter 3 Market Variables, Trends & Scope

3.1 Market segmentation & scope

3.1.1 Market Driver Analysis Robust pipeline in development Introduction of technological advancements Increasing investment from the companies and partnerships Growing prevalence of target diseases and increased demand for innovative medicine

3.1.2 Market Restrain Analysis Presence of ambiguous regulatory framework High prices of gene therapy medicines

3.2 Penetration & growth prospect mapping

3.3 Gene Therapy - SWOT Analysis, By Factor (political & legal, economic and technological)

3.4 Industry Analysis - Porter's

Chapter 4 Gene Therapy Market: Indication Type Estimates & Trend Analysis

4.1 Gene Therapy market: Indication Type movement analysis

4.2 Cancer

4.3 Cardiovascular Indication

4.4 Infectious diseases indication

4.5 Genetic diseases indication

4.6 Neurological diseases indication

4.7 Other indications

Chapter 5 Gene Therapy Market: Vector type Estimates & Trend Analysis

5.1 Gene Therapy market: Vector type movement analysis

5.2 Viral Vectors

5.3 Non-viral vectors

Chapter 6 Gene Therapy Market: Regional Estimates & Trend Analysis, by Indications Type and Component Type

6.1 Gene Therapy market share by region, 2013 & 2024

6.2 North America

6.2.1 U.S.

6.2.2 Canada

6.3 Europe

6.3.1 Germany

6.3.2 U.K.

6.4 Asia Pacific

6.4.1 China

6.4.2 Japan

6.5 Latin America

6.5.1 Brazil

6.6 Middle East and Africa

6.6.1 South Africa

Chapter 7 Competitive Landscape

7.1 Strategy framework

7.2 Market participation categorization

7.3 Company Profiles

7.3.1 UniQure N.V. Company Overview Financial Performance Product Benchmarking Strategic Initiatives

7.3.2 Spark Therapeutics LLC

7.3.3 Bluebird Bio

7.3.4 Celgene Corporation

7.3.5 GlaxoSmithKline PLC

7.3.6 Shire PLC

7.3.7 Cellectis

7.3.8 Sangamo Biosciences Inc.

7.3.9 ReGenX Bio. Inc.

7.3.10 Oxford Biomedica PLC

7.3.11 Voyager Therapeutics

7.3.12 Human Stem Cells Institute.

7.3.13 Dimension Therapeutics Inc.

7.3.14 Bristol Myers Squibb

7.3.15 Sanofi Genzyme

7.3.16 Applied Genetic Technologies Corporation

7.3.17 Chiesi Farmaceutici S.p.A.

7.3.18 Benitec BioPharma

7.3.19 Sibiono GeneTech Co. Ltd

7.3.20 Shanghai Sunway Biotech Co. Ltd.

7.3.21 Gensight Biologics S.A.

7.3.22 Transgene S.A.

7.3.23 Epeius Biotechnologies Corp

7.3.24 Calimmune Inc.

7.3.25 American Gene Technologies

7.3.26 Juno Therapeutics, Inc.

7.3.27 Biomarin Pharmaceuticals, Inc.

7.3.28 TaxusCardium Pharmaceuticals Inc.

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900